Press release
Global Geriatric Medicines Market Analysis: Indications, Therapeutics, Growth Trends and Forecast to 2020
Browse Geriatric Medicines Market by Indication Types (Arthritis, Cancer, Cardiovascular, Neurological, Osteoporosis, Respiratory), and Therapeutic Areas (Analgesics, Anticoagulants, Antidiabetic, Antihypertensive, Antipsychotics, Proton Pump Inhibitors, Statins) 2016-2020 at https://www.ihealthcareanalyst.com/report/geriatric-medicines-market/
Geriatric medicine is a branch of medicine concerned with clinical, remedial, preventive, and social aspects of disorders usually among people aged 65 years and above. Geriatric medicine is a subspecialty of internal medicine or family medicine that deals with the complex medical and psychosocial problems of older adults, and it is rapidly evolving into both a hospital-based specialty and a specialty concerned with community care. The geriatric population requires more palliative care and support as compared with younger adults due to reduced immunity of the geriatrics. Increasing chronic diseases among geriatrics and favorable government initiative toward geriatric care is driving demand for geriatric medicines worldwide.
The global geriatric medicines market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the indication types (arthritis, cancer, cardiovascular, neurological, osteoporosis, respiratory, etc.), and therapeutic areas (analgesics, anticoagulants, antidiabetic, antihypertensive, antipsychotics, proton pump inhibitors, statins, etc.), and forecasts growth trends (CAGR% - 2016 to 2020). The global geriatric medicines market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global geriatric medicines market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.
Major players operating in the global geriatric medicines market and included in this report are Abbott Laboratories, Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Eli Lilly and Company, Novartis AG, Pfizer, Inc., Merck & Company Inc., GlaxoSmithKline plc and Sanofi S.A.
To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/geriatric-medicines-market/
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
Ana Aitawa
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Phone: (314) 500-7508
Email: sales@ihealthcareanalyst.com
https://www.ihealthcareanalyst.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Geriatric Medicines Market Analysis: Indications, Therapeutics, Growth Trends and Forecast to 2020 here
News-ID: 443529 • Views: …
More Releases from iHealthcareAnalyst, Inc.
Global Amyotrophic Lateral Sclerosis Devices Market $19.5 Billion by 2029
The global market for amyotrophic lateral sclerosis devices or motor neuron disease devices anticipated to reach $19.5 billion by 2029, growing at a CAGR of 7.3% over the forecast period, driven by increasing incidence, rising geriatric population, lack of curative treatment, growing public awareness, and technological advancements in palliative care.
https://www.ihealthcareanalyst.com/global-amyotrophic-lateral-sclerosis-devices-market/
Amyotrophic lateral sclerosis or Lou Gehrig's disease or motor neuron disease (MND) is characterized by progressive degeneration of the motor nerve…
Global Blood Gas Monitoring Products Market Growing at CAGR of 6.2% to Reach $5. …
The global market for blood gas monitoring products is estimated to reach $5.5 billion by the end of 2025, expanding at a CAGR of 6.2% during the forecast period, supported by growing geriatric population, rising prevalence of chronic diseases, and technological advances.
The global blood gas monitoring devices market research report provides market size (Revenue US$ Million 2017 to 2025), market share analysis, growth trends and forecast (CAGR%, 2019 to 2025).…
Advances in Mobile Connectivity Services to Drive Telemedicine Technologies and …
According to a new market research report Telemedicine Technologies and Services Market 2015-2023 published by iHealthcareAnalyst, Inc., the global computer-aided detection market to reach US$ 73.2 Billion by 2023, expanding at a CAGR of 13.5% from 2018-2023.
Visit the Global Telemedicine Technologies and Services Market Analysis and Forecast 2018-2023 report at https://www.ihealthcareanalyst.com/report/telemedicine-technologies-services-market/
The global telemedicine technologies and services market newly published (updated 2018) report estimates the market size (US$ million 2015-2023)…
Global Internet Pharmacies Market to Cross US$ 100 Billion by 2023
The global internet pharmacies market is estimated to reach US$ 106 Billion by 2023, growing at a CAGR of 15.7% over the forecast period, driven by rising personal disposable income, lower prices, surge in internet penetration, stupendous growth of online retail market and a large number of online players entering the online healthcare product segment.
The major players are in a race to increase their share in the industry by…
More Releases for Ana
HISTORIC SANTA ANA LANDMARK REVITALIZED THROUGH ADAPTIVE REUSE ORDINANCE
Alliant Strategic delivers a solution by providing one of the first adaptive reuse apartment projects to fulfill a critical need for the local Santa Ana community. The newly renovated development, 888 on Main, will add 148 apartments to Downtown’s historic core, one of the most densely populated residential markets in the nation that suffers from an extreme housing shortage. With the building shell, core, mechanical systems, and underground parking already…
Antechamber Solo show Ana Mazzei
Ana Mazzei
Antechamber
12 November 2018– 5 January 2019
In her first solo exhibition at Green Art Gallery, Ana Mazzei fully embraces the notion of theatricality and
spectatorship, both very central to her practice, to present a group of new works specifically created for the space.
Titled Antechamber, the show is staged as an intermediary space between the real world outside the gallery and
an imaginary ‘other space’.
Walking along this in-between space, viewers have to negotiate…
Intravenous Solutions Market 2018-2025 Growth Factors Ana
This report studies the global Intravenous Solutions market, analyzes and researches the Intravenous Solutions development status and forecast in United States, EU, Japan, China, India and Southeast Asia.
This report focuses on the top players in global market, like
Baxter
Hospira
B. Braun Melsungen
Fresenius Kabi
Claris Lifesciences
Grifols
Vifor Pharma
JW Life Science
Market segment by Regions/Countries, this report covers
United States
EU
Japan
China
India
Southeast Asia
Browse the full report…
direct/ All Nippon Airways: ANA Interim results amendment
In line 5 of paragraph 1, Operating Profit is reported as having fallen to 696.1 billion yen. This is in fact the figure for Operating Costs. The correct figure for Operating Profit is 67.0 billion yen.
Please accept our apologies for this mistake. The first chart on the first page, entitled Consolidated Financial Performance, gives the correct figures.
The announcement distributed by Hugin directnews.
The issuer is solely responsible for the…
direct/ All Nippon Airways: ANA Interim FY07 Profitable
ANA Reports Profitable First Six Months to Fiscal Year 2007
- record revenue on strong international growth
TOKYO October 31, 2007 ANA Group today reported a record consolidated net profit of 105.5 billion yen on record revenue of 763.2 billion yen for first six months of fiscal year 2007, ended September 30, a 217% and 1.4% increase respectively. Net profit was boosted considerably by the sale of ANA Group´s hotel assets on…
direct/ All Nippon Airways: ANA Corporate Plan FY2007
Japan´s first all business Class Jet to Link Tokyo and Mumbai -
TOKYO January 25, 2007 ANA today announced its corporate plan for the 2007 fiscal year, April 1, 2007 - March 31, 2008. Fiscal 2007 constitutes the second year of ANA´s Medium-Term Strategy FY2006-2009, the aim of which is to establish ANA as Asia´s No 1 airline for quality, customer satisfaction and value creation in line with the future…
